SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Algorand (ALGO) is a cryptocurrency launched in 2019. Algorand has a current supply of 10,000,000,000 with 9,078,194,480.417637 in circulation. The last known price of Algorand is 0.09693394 USD and is up 3.39 over the last 24 hours. It is currently trading on 586 active market(s) with $57,858,585.39 traded over the last 24 hours. More information can be found at http://algorand.foundation.

Algorand

ALGOs weak price action and difficulty holding or reclaiming the 10-cent area are driving debate, with bearish traders warning of further downside and bullish traders arguing the token is near a bottom and could rebound with a broader altcoin recovery. Some bulls also point to Algorands post-quantum technology and tokenization potential, but those remain longer-term arguments rather than a confirmed near-term catalyst.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candels SITC clinical and biomarker updates across its prostate, lung and glioblastoma programs have renewed attention, alongside expectations for a Q4 BLA filing for CAN-2409 after positive Phase 3 prostate results. Bulls see the data and regulatory milestone as potential value drivers, while skeptics focus on filing uncertainty, CEO transparency and dilution risk.

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

Astrazeneca plc

AstraZeneca PLC

Reports of AstraZeneca making a nonbinding offer for Rhythm Pharmaceuticals are drawing attention, with traders weighing the potential addition of rare-obesity treatments against uncertainty about whether a deal will proceed. Some are also debating whether AZN should pursue other obesity assets instead.

Newmont Corp. engages in the exploration and acquisition of gold properties, containing copper, silver, lead, zinc or other metals. It operates through the following geographical segments: Papua New Guinea, Australia, Ghana, Suriname, Argentina, Peru, Mexico, Canada, and U.S. The company was founded by William Boyce Thompson on May 2, 1921 and is headquartered in Denver, CO.

Newmont Corp

Newmont is drawing attention amid renewed strength in gold miners, with traders tying the sectors appeal to golds safe-haven role and concerns about inflation and currency debasement. The community is broadly bullish on miners but divided on NEMs near-term path, with many technical posts warning that its pullback after a strong advance may not be finished.

Fervo Energy Co. operates as a energy company. It builds and operates power facilities in extracting geothermal energy. The company was founded by Jack Norbeck and Timothy Latimer in 2017 and is headquartered in Berkeley, CA.

Fervo Energy Co. - Ordinary Shares - Class A

Fervo Energy Co

FRVO is drawing attention amid a sharp rebound and unusual call activity, with traders speculating about a possible catalyst but no specific new deal confirmed in the discussion. The broader debate remains whether Cape Stations first-power milestone and Google-backed demand outweigh concerns about geothermal execution, water recovery, transmission constraints and claims in a short-seller report.

Alcoa Corp. engages in the bauxite mining, alumina refining, and aluminum smelting and casting. It operates through the Alumina and Aluminum segments. The Alumina segment consists of a refining system, including the mining of bauxite, which is then refined into alumina, a compound of aluminum and oxygen that is the raw material used by smelters to produce aluminum metal. The Aluminum segment is composed of smelting and casthouse system. The company was founded by Charles Martin Hall on July 9, 1886 and is headquartered in Pittsburgh, PA.

Alcoa Corp

Unusual options activity and volatile trading have traders divided over Alcoas direction: some expect further cyclical downside, while others point to long-term aluminum demand and expanded assets as reasons for optimism. The discussion also weighs alumina-price exposure and financing and closing considerations around the companys acquisition plans.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshires latest quarterly results are drawing attention, with weaker insurance performance weighing on operating earnings while a sharp increase in share repurchases is viewed by supporters as a sign management sees value in the stock. The community is split between welcoming the buybacks and questioning whether they offset the earnings softness and limited investment opportunities.

Airbnb, Inc. engages in the management and operation of an online marketplace. Its marketplace model connects hosts and guests online or through mobile devices to book spaces. The company was founded by Brian Chesky, Nathan Blecharczyk and Joseph Gebbia in 2007 and is headquartered in San Francisco, CA.

Airbnb Inc - Ordinary Shares - Class A

Airbnb Inc

Airbnbs Q3 results beat expectations and its raised outlook, alongside a new buyback authorization, are driving the sharp rally. Traders are upbeat about accelerating bookings and growth, while some question take-rate and cash-flow trends and whether the gains can hold amid a weak broader market.

Datadog, Inc. engages in the development of a monitoring and analytics platform for developers, information technology operations teams and business users. Its platform integrates and automates infrastructure monitoring, application performance monitoring and log management to provide real-time observability of its customers' entire technology stack. The company was founded by Olivier Pomel and Alexis Lê-Quôc on June 4, 2010 and is headquartered in New York, NY.

Datadog Inc - Ordinary Shares - Class A

Datadog Inc

Datadogs post-earnings selloff is the dominant discussion: strong Q3 results were overshadowed by an in-line Q4 revenue outlook that implies little sequential growth, alongside concern about reduced spending from its largest AI customer and slower large-account additions. Traders debate whether the drop is an overreaction and a buying opportunity or a warning about decelerating growth and a rich valuation.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.17847452 USD and is down -3.32 over the last 24 hours. It is currently trading on 1894 active market(s) with $2,362,443,159.56 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRPs continued slide and perceived underperformance dominate discussion, with traders debating broader crypto-market weakness and uncertainty around the Clarity Act after election results alongside XRP-specific concerns about Ripples token supply, utility and leadership. Some are buying the dip, while many remain bearish and expect more downside.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

New Strong Sell Stocks for October 14th

ADDYY, CELC and CNL have been added to the Zacks Rank #5 (Strong Sell) List on October 14, 2026.

Why Celcuity Stock Was a Winner on Wednesday

Key PointsThis is a breast cancer treatment, Revtorpyk...

Shredding Pounds, Trading Stocks—Lilly’s Potential Obesity Blockbuster and other Biotechs in Play

The biotech tape is entering a catalyst-heavy stretch, with NeOnc Technologies Holdings (NASDAQ:NTHI), Connect Biopharma (NASDAQ:CNTB), Valion Bio (NASDAQ:VBIO), Eli Lilly and Company (NYSE:LLY), Celcuity (NASDAQ:CELC), and Capricor Therapeutics (NASDAQ:CAPR) heading into important stretches, but for very different reasons.

Celcuity Analysts Slash Their Forecasts After Q2 Loss

Celcuity Inc (NASDAQ:CELC) reported better-than-expected Q2 losses of $1.07 per share. Analysts are optimistic with price target cuts by Needham and Stifel.read more...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC PR Newswire NEW YORK, Aug. 6, 2026 NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is...

CELC SHAREHOLDER ALERT: Celcuity Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Celcuity Inc. (Celcuity or the Company) (NASDAQ: CELC) investors concerning the Companys and/or members of its senior managements possible violation of the federal securities laws or other unlawful business...

CELC Investors Have Opportunity to Join Celcuity Inc. Fraud Investigation with SBS Law

Schall, Brown & Schwartz LLP (SBS), a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Celcuity Inc. (Celcuity or the Company) (NASDAQ: CELC) for violations of the securities laws.INVESTIGATION DETAILS: The investigation focuses on...

CELC Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Celcuity Inc. (NASDAQ: CELC) Investors to Contact the Firm

CELC Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Celcuity Inc. (NASDAQ: CELC) Investors to Contact the Firm CELC Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Celcuity Inc. (NASDAQ: CELC) Investors to Contact the Firm PR Newswire RADNOR, Pa., July 31, 2026 RADNOR...

INVESTOR ALERT: Pomerantz Law Firm Investigates ClaimsnOn Behalf of Investors of Celcuity Inc. - CELC

INVESTOR ALERT: Pomerantz Law Firm Investigates ClaimsnOn Behalf of Investors of Celcuity Inc. - CELC INVESTOR ALERT: Pomerantz Law Firm Investigates ClaimsnOn Behalf of Investors of Celcuity Inc. - CELC PR Newswire NEW YORK, July 30, 2026 NEW YORK, July 30, 2026 /PRNewswire/ -- Pomerantz LLP is...

NASDAQ: CELC Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Celcuity Inc. (NASDAQ: CELC) Investors to Contact the Firm

Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by Celcuity Inc. (NASDAQ: CELC) on behalf of investors who purchased or acquired Celcuity Inc. securities and experienced...

$CELC Q3 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of -$1.21 down -55.13% YoY
• Celcuity expects research and development and selling, general and administrative expenses to increase as REVTORPYK commercialization ramps up and trials continue; Celcuity believes current cash resources will fund operations through 2029.

Stocktwits

Celcuity Inc

 Q3 '26 Earnings Results & Recap

• Reported GAAP EPS of -$1.21 down -55.13% YoY
• Celcuity expects research and development and selling, general and administrative expenses to increase as REVTORPYK commercialization ramps up and trials continue; Celcuity believes current cash resources will fund operations through 2029.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

• Reported GAAP EPS of -$1.21 down -55.13% YoY
• Celcuity expects research and development and selling, general and administrative expenses to increase as REVTORPYK commercialization ramps up and trials continue; Celcuity believes current cash resources will fund operations through 2029.

Celcuitys quarterly net loss reached $73.3M as SG&A rose; competitors and reimbursement constraints threaten commercialization, while operating cash use and uncertain access to future capital add financing risk.

Celcuitys REVTORPYK received FDA approval and a preferred Category 1 NCCN recommendation; VIKTORIA-1 PIK3CA-mutant results reported median PFS of 11.1 months versus 5.6 months, and cash resources support operations through 2029.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

CELC Stock Clocks Best Day In About 2 Months On First FDA Approval For Cancer Drug

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>The FDA approved gedatolisib in combination with cancer drug fulvestrant, with or without Pfizer’s palbociclib.</li><li>This approval gives the company its first marketed product and transitions it from a pure development-stage firm to one with a commercial opportunity.</li><li>Celcuity’s pipeline remains centered on gedatolisib, with ongoing work in earlier lines of breast cancer and prostate cancer.</li></ul> Shares of Celcuity Inc. (CELC) jumped 7% on Tuesday after the U.S. Food and Drug Administration approved its drug gedatolisib in combination with cancer drug fulvestrant, with or without Pfizer’s palbociclib.The approval covers adults with advanced hormone receptor-positive, HER2-negative breast cancer without a PIK3CA mutation whose disease progressed after prior hormone therapy.The stock on Tuesday clocked its best day since May.<h2 class="st-heading-2">CELC's Trial Results</h2>The decision is based on the late-stage VIKTORIA-1 trial. The three-drug combination (gedatolisib + palbociclib + fulvestrant) cut the risk of disease progression or death by 76% and extended median progression-free survival to 9.3 months, compared with just two months on fulvestrant alone.The two-drug combination (gedatolisib + fulvestrant) reduced risk by 67%, with a median PFS of 7.4 months. Response rates were also significantly higher with both gedatolisib regimens.Progression-Free Survival (PFS) is the length of time during and after treatment that a patient lives with a disease, like cancer, without it getting worse. It measures how long a therapy successfully keeps the tumor from growing, spreading, or returning.Gedatolisib is given as a weekly intravenous infusion. The company intends to launch the drug commercially in the third quarter.<h2 class="st-heading-2">Company Pipeline And Impact</h2>Gedatolisib, in-licensed from Pfizer in 2021, is Celcuity’s sole late-stage asset and has been the focus of its entire development program.This approval gives the company its first marketed product and transitions it from a pure development-stage firm to one with a commercial opportunity in advanced breast cancer. Celcuity’s pipeline remains centered on gedatolisib, with ongoing work in earlier lines of breast cancer and prostate cancer.Celcuity had cash, cash equivalents, and short-term investments of $387.1 million as of the end of last quarter. Celcuity then said its current cash position, together with its debt facility, is expected to fund operations through 2027.<h2 class="st-heading-2">How Did CELC Retail Traders React?</h2>On Stocktwits, retail sentiment around CELC stock stayed within the bullish territory over the past 24 hours, while message volume stayed at extremely high levels.A Stocktwits user opined that the stock should have rallied further on “such a big news.”<stembedurl>https://www.stocktwits.com/bullwink/message/659051202</stembedurl>Another user voiced hopes for a buyout of the company.<stembedurl>https://www.stocktwits.com/LarInvests/message/659050394</stembedurl>A third user termed the stock a “huge opportunity” under $115.<stembedurl>https://www.stocktwits.com/kellymone2/message/659049854</stembedurl>According to data from Koyfin, all 12 analysts covering CELC stock rate it ‘Buy’ or higher. The stock has a 12-month average price target of $160.64, representing a potential upside of about 45% from its last close.<a href="https://stocktwits.com/symbol/CELC">CELC stock</a> has gained 11% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/lcid-stock-tumbles-on-bankruptcy-rumors-lucid-says-reports-are-completely-false/cZZR42GR7qo">LCID Stock Tumbles On Bankruptcy Rumors — Lucid Says Reports Are ‘Completely False’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Celcuity logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Gedatolisib, in-licensed from Pfizer in 2021, is Celcuity’s sole late-stage asset.

Vanguard Total Stock Market ETF

SPDR S&P Biotech ETF

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$66.79
Prev Close	$64.04
Open	$67.15
Dividend Yield	0.00%
50-Day Moving Average	$75.11
Beta	1.21
Avg. Volume	1.8M
PE Ratio	-14.18

52-Week High	$151.02
52-Week Low	$53.54
Market Capitalization	$3.28B
EPS (Annual)	-$3.79
Price to Book	-44.31
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

CELC Fundamentals